TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China. This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks. The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biotechnology company based in China, specializing in the development of innovative biologic drugs. The company focuses on creating treatments for autoimmune diseases, with its flagship product, Telitacicept, being a dual-target fusion protein aimed at conditions such as myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis.
Average Trading Volume: 11,626,015
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.96B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.